NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis $10.18 -0.08 (-0.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.09▼$10.4450-Day Range$9.36▼$10.8452-Week Range$9.02▼$14.57Volume3.01 million shsAverage Volume2.81 million shsMarket Capitalization$3.02 billionP/E RatioN/ADividend YieldN/APrice Target$17.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside72.6% Upside$17.57 Price TargetShort InterestBearish8.73% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment1.13Based on 5 Articles This WeekInsider TradingSelling Shares$136,525 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to $0.19 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.17 out of 5 starsMedical Sector180th out of 936 stocksPharmaceutical Preparations Industry75th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amicus Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.73% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 0.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 3.4 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $136,525.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.12) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -20.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -20.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 18.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesJuly 10, 2024 | insidertrades.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells $61,000.00 in StockJuly 24 at 6:05 PM | globenewswire.comIn NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service FundJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 5:05 AM | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 1, 2024 | globenewswire.comIn NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial ReviewJune 27, 2024 | globenewswire.comIn NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by JuryJune 26, 2024 | globenewswire.comIn NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut BanJune 13, 2024 | globenewswire.comIn NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction StandardJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 11, 2024 | globenewswire.comIn NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection RegimeJune 5, 2024 | globenewswire.comIn NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private FundsJune 5, 2024 | globenewswire.comAmicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 24, 2024 | msn.comDo Options Traders Know Something About Amicus (FOLD) Stock We Don't?May 20, 2024 | seekingalpha.comAmicus Therapeutics: Too Cheap At Under $10 A ShareMay 14, 2024 | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14, 2024 | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptSee More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$17.57 High Stock Price Target$22.00 Low Stock Price Target$13.00 Potential Upside/Downside+74.0%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-34.73% Pretax Margin-33.17% Return on Equity-77.08% Return on Assets-13.79% Debt Debt-to-Equity Ratio2.97 Current Ratio3.03 Quick Ratio2.61 Sales & Book Value Annual Sales$399.36 million Price / Sales7.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book18.36Miscellaneous Outstanding Shares296,200,000Free Float289,683,000Market Cap$2.99 billion OptionableOptionable Beta0.71 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate CommunicationsMore ExecutivesKey CompetitorsBiohavenNYSE:BHVNBausch Health CompaniesNYSE:BHCArrowhead PharmaceuticalsNASDAQ:ARWRTurning Point TherapeuticsNASDAQ:TPTXPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 82,065 shares on 7/26/2024Ownership: 0.420%AlphaCentric Advisors LLCBought 27,500 shares on 7/26/2024Ownership: 0.068%Legato Capital Management LLCBought 91,153 shares on 7/26/2024Ownership: 0.034%China Universal Asset Management Co. Ltd.Sold 21,951 shares on 7/20/2024Ownership: 0.012%Assenagon Asset Management S.A.Bought 845,407 shares on 7/18/2024Ownership: 0.285%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions How have FOLD shares performed this year? Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD shares have decreased by 28.3% and is now trading at $10.18. View the best growth stocks for 2024 here. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.04. The business's revenue was up 27.9% on a year-over-year basis. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Amicus Therapeutics' major shareholders? Top institutional shareholders of Amicus Therapeutics include Bank of New York Mellon Corp (0.42%), Assenagon Asset Management S.A. (0.29%), M&G Plc (0.25%) and Transcend Capital Advisors LLC (0.11%). Insiders that own company stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout, Michael Raab, Margaret G Mcglynn and Burke W Whitman. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV) and Exelixis (EXEL). This page (NASDAQ:FOLD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
